Exploring RNA interference as a therapeutic strategy for renal disease

Area of Science:

• Molecular Biology
• Renal Physiology
• RNA Interference Therapeutics

Background:

• Short interfering RNA (siRNA) selectively suppresses gene expression in mammalian cells.
• Selective in vivo delivery of siRNA to the kidney remains a challenge.
• Gene silencing in glomerular cells is crucial for treating kidney diseases.

Purpose of the Study:

• To investigate the efficacy and therapeutic potential of intra-arterial siRNA delivery combined with electroporation for gene silencing in rat kidneys.
• To compare the potency of siRNA with antisense oligodeoxynucleotide (ASODN) in mesangial cells.
• To evaluate the therapeutic effect of targeting TGF-beta1 in experimental glomerulonephritis.

Main Methods:

• siRNA transfection into cultured rat mesangial cells (MCs).
• Intra-arterial delivery of siRNA targeting luciferase and enhanced green fluorescent protein (EGFP) in rat kidneys.
• In vivo assessment of gene silencing via luciferase and EGFP expression.
• RNA interference (RNAi) targeting TGF-beta1 in an experimental glomerulonephritis model.

Main Results:

• siRNA demonstrated over 1000-fold greater potency than ASODN in suppressing transgene expression in MCs.
• siRNA targeting luciferase significantly inhibited its expression in rat kidneys.
• EGFP expression was reduced in glomerular MCs of transgenic rats following siRNA delivery.
• RNAi targeting TGF-beta1 suppressed both mRNA and protein levels, ameliorating matrix expansion in glomerulonephritis.

Conclusions:

• Intra-arterial siRNA delivery with electroporation is an effective method for gene silencing in the kidney glomerulus.
• siRNA-directed TGF-beta1 silencing holds therapeutic promise for fibrotic kidney diseases.
• Vector-based RNAi also proved effective in inhibiting TGF-beta1 expression in vitro and in vivo.